154 349

Cited 0 times in

Clinical results of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in children with advanced stage rhabdomyosarcomastage rhabdomyosarcoma

DC Field Value Language
dc.contributor.author김남균-
dc.contributor.author김현옥-
dc.contributor.author김효선-
dc.contributor.author서창옥-
dc.contributor.author유철주-
dc.date.accessioned2014-12-19T17:10:24Z-
dc.date.available2014-12-19T17:10:24Z-
dc.date.issued2012-
dc.identifier.issn1011-8934-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/90910-
dc.description.abstractRegardless of improvement in cure of Rhabdomyosarcoma (RMS), the results in treatment of advanced stage of RMS in children are still dismal. Recently, high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (HDC/APBSCT) has been tried to manage the advanced high-risk RMS patients. We investigated the effectiveness of HDC/APBSCT by reviewing the clinical records of high-risk pediatric RMS patients in single institute database. Over twenty years, 37 patients were diagnosed as RMS with high-risk at the time of first diagnosis. These patients were classified as two groups according to treatment method. The first group was HDC/APBSCT and the other was conventional multi-agent chemotherapy group. Differences of clinical results between the two groups were analyzed. The median age of patients was 5 yr, ranging from 6 months to 15 yr. The 5-yr event free survival rate (EFS) of all patients was 24.8% ± 4.8%. HDC/APBSCT group and conventional multi-agent chemotherapy group were 41.3% ± 17.8% and 16.7% ± 7.6% for 5-yr EFS, respectively (P = 0.023). There was a significant difference in the result of HDC/APBSCT between complete remission or very good partial response group and poor response group (50% ± 20.4% vs 37.5% ± 28.6%, P = 0.018). HDC/APBSCT can be a promising treatment modality in high-risk RMS patients.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfJOURNAL OF KOREAN MEDICAL SCIENCE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdolescent-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHCarboplatin/administration & dosage-
dc.subject.MESHChild-
dc.subject.MESHChild, Preschool-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHEtoposide/administration & dosage-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHIfosfamide/administration & dosage-
dc.subject.MESHInfant-
dc.subject.MESHMale-
dc.subject.MESHPeripheral Blood Stem Cell Transplantation*-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRhabdomyosarcoma/drug therapy*-
dc.subject.MESHRhabdomyosarcoma/mortality-
dc.subject.MESHRhabdomyosarcoma/pathology-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTransplantation, Autologous-
dc.subject.MESHTreatment Outcome-
dc.titleClinical results of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in children with advanced stage rhabdomyosarcomastage rhabdomyosarcoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pediatrics (소아과학)-
dc.contributor.googleauthorNam Kyun Kim-
dc.contributor.googleauthorHyo Sun Kim-
dc.contributor.googleauthorChang-Ok Suh-
dc.contributor.googleauthorHyun Ok Kim-
dc.contributor.googleauthorChuhl Joo Lyu-
dc.identifier.doi22969254-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00355-
dc.contributor.localIdA01122-
dc.contributor.localIdA01201-
dc.contributor.localIdA01919-
dc.contributor.localIdA02524-
dc.relation.journalcodeJ01517-
dc.identifier.eissn1598-6357-
dc.identifier.pmid22969254-
dc.subject.keywordBone Marrow Transplantation-
dc.subject.keywordChemotherapy-
dc.subject.keywordChildren-
dc.subject.keywordRhabdomyosarcoma-
dc.contributor.alternativeNameKim, Nam Kyun-
dc.contributor.alternativeNameKim, Hyun Ok-
dc.contributor.alternativeNameKim, Hyo Sun-
dc.contributor.alternativeNameSuh, Chang Ok-
dc.contributor.alternativeNameLyu, Chuhl Joo-
dc.contributor.affiliatedAuthorKim, Nam Kyun-
dc.contributor.affiliatedAuthorKim, Hyun Ok-
dc.contributor.affiliatedAuthorKim, Hyo Sun-
dc.contributor.affiliatedAuthorSuh, Chang Ok-
dc.contributor.affiliatedAuthorLyu, Chuhl Joo-
dc.citation.volume27-
dc.citation.number9-
dc.citation.startPage1066-
dc.citation.endPage1072-
dc.identifier.bibliographicCitationJOURNAL OF KOREAN MEDICAL SCIENCE, Vol.27(9) : 1066-1072, 2012-
dc.identifier.rimsid33208-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.